Humira (adalimumab) is used to treat several autoimmune conditions. The drug typically stays in your system for a few months after your final dose. This article explains how long Humira may remain in ...

According to a latest report by Coherent Market Insights, the global Humira Market is projected to be valued at USD 4.68 Bn in 2025, but is expected to decline to USD 1.20 Bn by 2032, experiencing a ...

The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands patient access in the process. Full interchangeability approved: The FDA has ...

The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...

The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...

Similar PK, efficacy, safety, and immunogenicity data were observed between the adalimumab-aaty and Humira switching group vs the Humira maintenance group. The Food and Drug Administration (FDA) has ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs. The FDA has granted interchangeability designation to Celltrion’s Yuflyma ...

Humira (adalimumab) treats certain types of arthritis and inflammatory diseases. This prescription drug is a liquid for injection under your skin. Humira may not be safe to receive while pregnant but ...